Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 5, 2014, Pages 589-598

  Yang, K ^a   Woodhead, J L ^b   Watkins, P B ^a,b   Howell, B A ^b   Brouwer, K L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CHENODEOXYCHOLIC ACID; LITHOCHOLIC ACID; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PIOGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ABCB11 PROTEIN, HUMAN; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CELL CYCLE; DRUG DISPOSITION; DRUG SAFETY; HOMEOSTASIS; HUMAN; JAUNDICE; LIVER CELL; LIVER TOXICITY; MALE; NONHUMAN; PREDICTION; RAT; SENSITIVITY ANALYSIS; SIMULATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; DRUG-INDUCED LIVER INJURY; PHYSIOLOGY; REGRESSION ANALYSIS; SPECIES DIFFERENCE; TOXICITY;

ALANINE TRANSAMINASE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; CHROMANS; DRUG-INDUCED LIVER INJURY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, BIOLOGICAL; RATS; REGRESSION ANALYSIS; SPECIES SPECIFICITY; THIAZOLIDINEDIONES;

EID: 84908152658     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.158     Document Type: Article

References (49)

1. Temple, R. J. & Himmel, M. H. Safety of newly approved drugs: implications for prescribing. JAMA 287, 2273-2275 (2002).
2. Watkins, P. B. & Whitcomb, R. W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338, 916-917 (1998).
3. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 26 April 1999. . Accessed 25 January 2014.
4. Isley, W. L. Hepatotoxicity of thiazolidinediones. Expert Opin. Drug Saf. 2, 581-586 (2003).
5. Smith, M. T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16, 679-687 (2003).
6. Chojkier, M. Troglitazone and liver injury: in search of answers. Hepatology 41, 237-246 (2005).
7. Perez, M. J. & Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 15, 1677-1689 (2009).
8. Maillette de Buy Wenniger, L. & Beuers, U. Bile salts and cholestasis. Dig. Liver Dis. 42, 409-418 (2010).
9. Jansen, P. L. et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117, 1370-1379 (1999).
10. van Mil, S. W. et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 127, 379-384 (2004).
11. Morgan, R. E. et al. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol. Sci. 136, 216-241 (2013).
12. Dawson, S., Stahl, S., Paul, N., Barber, J. & Kenna, J. G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138 (2012).
13. Pedersen, J. M. et al. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol. Sci. 136, 328-343 (2013).
14. Funk, C., Ponelle, C., Scheuermann, G. & Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635 (2001).
15. Yang, K., Yue, W., Koeck, K. & Brouwer, K. L. R. Interaction of troglitazone sulfate with hepatic basolateral and canalicular transport proteins. 2011 AAPS Annual Meeting and Exposition Washington, DC, 23-27 October 2011.
16. Marion, T. L., Leslie, E. M. & Brouwer, K. L. R. Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of druginduced hepatotoxicity. Mol. Pharm. 4, 911-918 (2007).
17. Shoda, L. K., Woodhead, J. L., Siler, S. Q., Watkins, P. B. & Howell, B. A. Linking physiology to toxicity using DILIsym, a mechanistic mathematical model of drug-induced liver injury. Biopharm. Drug Dispos. 35, 33-49 (2014).
18. Howell, B. A. et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: a mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn. 39, 527-541 (2012).
19. Woodhead, J. L. et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J. Pharmacol. Exp. Ther. 342, 529-540 (2012).
20. Woodhead, J. L. et al. Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacometrics Syst. Pharmacol. 3, e123 (2014).
21. Loi, C. M., Randinitis, E. J., Vassos, A. B., Kazierad, D. J., Koup, J. R. & Sedman, A. J. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J. Clin. Pharmacol. 37, 1114-1120 (1997).
22. Izumi, T. et al. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J. Pharmacol. Exp. Ther. 277, 1630-1641 (1996).
23. Izumi, T., Hosiyama, K., Enomoto, S., Sasahara, K. & Sugiyama, Y. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J. Pharmacol. Exp. Ther. 280, 1392-1400 (1997).
24. Trottier, J., Caron, P., Straka, R. J. & Barbier, O. Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin. Pharmacol. Ther. 90, 279-286 (2011).
25. Watkins, P. B. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 33, 1-5 (2005).
26. Urban, T. J., Goldstein, D. B. & Watkins, P. B. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics 13, 735-738 (2012).
27. Leslie, E. M., Watkins, P. B., Kim, R. B. & Brouwer, K. L. R. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321, 1170-1178 (2007).
28. Herman, J. R. et al. Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. Toxicol. Sci. 68, 226-236 (2002).
29. Greim, H. et al. Mechanism of cholestasis. 6. Bile acids in human livers with or without biliary obstruction. Gastroenterology 63, 846-850 (1972).
30. García-Cañaveras, J. C., Donato, M. T., Castell, J. V. & Lahoz, A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLCMRM-MS-validated method. J. Lipid Res. 53, 2231-2241 (2012).
31. Hofmann, A. F. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36, 703-722 (2004).
32. Shoda, J., Tanaka, N., He, B. F., Matsuzaki, Y., Osuga, T. & Miyazaki, H. Alterations of bile acid composition in gallstones, bile, and liver of patients with hepatolithiasis, and their etiological significance. Dig. Dis. Sci. 38, 2130-2141 (1993).
33. Fischer, S., Beuers, U., Spengler, U., Zwiebel, F. M. & Koebe, H. G. Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin. Chim. Acta. 251, 173-186 (1996).
34. Trauner, M., Wagner, M., Fickert, P. & Zollner, G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 39, S111-S124 (2005).
35. Ieiri, I., Higuchi, S. & Sugiyama, Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for interindividual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5, 703-729 (2009).
36. Lang, C. et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17, 47-60 (2007).
37. Meier, Y. et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J. Gastroenterol. 14, 38-45 (2008).
38. Pfeifer, N. D. et al. Effect of ritonavir on (99m)technetium-mebrofenin disposition in humans: a semi-PBPK modeling and in vitro approach to predict transporter-mediated DDIs. CPT Pharmacometrics Syst. Pharmacol. 2, e20 (2013).
39. Kusuhara, H. Imaging in the study of membrane transporters. Clin. Pharmacol. Ther. 94, 33-36 (2013).
40. Livertox Database: pioglitazone. . Accessed 4 April 2014.
41. Chu, X. et al.; International Transporter Consortium. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin. Pharmacol. Ther. 94, 126-141 (2013).
42. Loi, C. M., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J. & Koup, J. R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. J. Clin. Pharmacol. 39, 920-926 (1999).
43. Eckland, D. A. & Danhof, M. Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes 2, S234-S242 (2000).
44. Köck, K. et al. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 42, 665-674 (2014).
45. Marion, T. L., Perry, C. H., St Claire, R. L. 3rd & Brouwer, K. L. R. Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes. Toxicol. Appl. Pharmacol. 261, 1-9 (2012).
46. Ansede, J. H., Smith, W. R., Perry, C. H., St Claire, R. L. 3rd & Brouwer, K. R. An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwichcultured rat hepatocytes. Drug Metab. Dispos. 38, 276-280 (2010).
47. Griffin, L. M., Watkins, P. B., Perry, C. H., St Claire, R. L. 3rd & Brouwer, K. L. R. Combination lopinavir and ritonavir alter exogenous and endogenous bile acid disposition in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 41, 188-196 (2013).
48. Yang, K., Köck, K., Sedykh, A., Tropsha, A. & Brouwer, K. L. R. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J. Pharm. Sci. 102, 3037-3057 (2013).
49. Rodrigues, A. D., Lai, Y., Cvijic, M. E., Elkin, L. L., Zvyaga, T. & Soars, M. G. Druginduced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab. Dispos. 42, 566-574 (2014).